The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies

Critical Care Medicine

Volumn 39, Issue 5, 2011, Pages 1104-1112

  Li, Yan ^a   Sun, Jun Feng ^a   Cui, Xizhong ^a   Mani, Haresh ^b   Danner, Robert L ^a   Li, Xuemei ^a,c   Su, Jun Wu ^a,d   Fitz, Yvonne ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

animal models; heparin; infection; metaregression analysis; pneumonia; sepsis; treatment

Indexed keywords

ANTIBIOTIC AGENT; FIBRINOGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RANTES; SODIUM CHLORIDE; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ESCHERICHIA COLI; FIBRINOGEN BLOOD LEVEL; HISTOPATHOLOGY; LUNG INJURY; LUNG LAVAGE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; REGRESSION ANALYSIS; SEPSIS; SURGICAL INFECTION; SURVIVAL; SYSTEMATIC REVIEW;

EID: 79955481485     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31820eb718     Document Type: Conference Paper

References (54)

1. Schouten M, Wiersinga WJ, Levi M, et al: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83:536-545 (Pubitemid 351966862)
2. Minneci PC, Deans KJ, Cui X, et al: Anti-thrombotic therapies for sepsis: A need for more studies. Crit Care Med 2006; 34: 538-541 (Pubitemid 43145636)
3. Barochia AV, Li Y, Cui X, et al: Antithrom-bosis trials: Should we test therapeutic hep-arin adjusted based on activated partial thromboplastin time in septic shock? Crit Care Med 2009; 37:1486-1487
4. Jaimes F, De La Rosa G, Morales C, et al: Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37:1185-1196
5. Zarychanski R, Doucette S, Fergusson D, et al: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008; 36:2973-2979
6. Angus DC, Wax RS: Epidemiology of sepsis: An update. Crit Care Med 2001; 29(Suppl 7):S109-S116 (Pubitemid 32681592)
7. Li Y, Cui X, Li X, et al: Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med 2008; 34:568-577 (Pubitemid 351623024)
8. Satterthwaite FE: An approximate distribu-tion of estimates of variance components. Biometrics 1946; 2:110-114
9. Klein JP, Moeschberger ML: Survival Analy-sis: Techniques for Censored and Truncated Data. Second Edition. New York, NY, Springer, 2003
10. Kleinbaum DG, Kupper LL, Muller KE, et al: Applied Regression Analysis and Other Mul-tivariable Methods. Third Edition. Pacific Grove, CA, Duxbury Press, 1998
11. Higgins JP, Thompson SG: Quantifying het-erogeneity in a meta-analysis. StatMed2002; 21:1539-1558
12. van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in meta-analysis: multi-variate approach and meta-regression. Stat Med 2002; 21:589-624 (Pubitemid 34141379)
13. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188 (Pubitemid 17189972)
14. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634 (Pubitemid 27387172)
15. Duval S, Tweedie R: A nonparametric "trim and fill" method of accounting for publica-tion bias in meta-analysis. J Am Stat Assoc 2000; 95:89-98
16. Hirsh J, Bauer KA, Donati MB, et al: Paren-teral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(Suppl 6):141S-159S (Pubitemid 351892966)
17. Su J, Cui X, Li Y, et al: SB203580, a p38 inhibitor, improved cardiac function but worsened lung injury and survival during Escherichia coli pneumonia in mice. J Trauma 2010; 68:1317-1327
18. Bahrami S, Paul E, Redl H, et al: Therapeutic modalities to ameliorate endotoxin induced DIC in the rats. Prog Clin Biol Res 1989; 308:977-982
19. Chalkiadakis G, Kostakis A, Karayannacos PE, et al: The effect of heparin upon fibrin-opurulent peritonitis in rats. Surg Gynecol Obstet 1983; 157:257-260 (Pubitemid 13007116)
20. Coalson JJ, Benjamin B, Archer LT, et al: Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circ Shock 1978; 5:423-437 (Pubitemid 9078598)
21. Corrigan JJ Jr, Kiernat JF: Effect of heparin in experimental gram-negative septicemia. JInfect Dis 1975; 131:138-143
22. Davidson RK, Cardenas A, Buruttil RW: The effects of heparin and low molecular weight dextran on survival after fibrinopurulent peri-tonitis. Surg Gynecol Obstet 1981; 153: 327-331 (Pubitemid 11057161)
23. Dickneite G, Czech J: Combination of anti-biotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of ex-perimental Klebsiella pneumoniae sepsis. Thromb Haemost 1994; 71:768-772 (Pubitemid 24177967)
24. Dunn DL, Mach PA, Cerra FB, et al: The role of heparin in guinea pig gram negative bac-terial sepsis. J Surg Res 1983; 34:479-485 (Pubitemid 13099746)
25. Echtenacher B, Weigl K, Lehn N, et al: Tu-mor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001; 69: 3550-3555 (Pubitemid 32493266)
26. Evangelista BS, Green TJ, Gwilt DJ, et al: An experimental study of current therapeutic approaches to endotoxin shock. Arch Int Pharmacodyn Ther 1969; 180:57-67
27. Filkins JP, Di Luzio NR: Heparin protection in endotoxin shock. Am J Physiol 1968; 214: 1074-1077
28. Gaskins RA Jr, Dalldorf FG: Experimental meningococcal septicemia. Effect of heparin therapy. Arch Pathol Lab Med 1976; 100: 318-324 (Pubitemid 8190710)
29. Griffin MP, Gore DC, Zwischenberger JB, et al: Does heparin improve survival in experi-mental porcine gram-negative septic shock? Circ Shock 1990; 31:343-349 (Pubitemid 20220911)
30. Gupta S, Jain PK: Low-dose heparin in ex-perimental peritonitis. Eur Surg Res 1985; 17:167-172
31. Hau T, Simmons RL: Heparin in the treat-ment of experimental peritonitis. Ann Surg 1978; 187:294-298
32. Herlache JL, Winkler JM, Gehrke C: Im-proved survival in refractory endotoxin shock with heparin and dextrose. Mich Med 1974; 73:191-194
33. Hirano T, Forbes SR, Robinson GT, et al: The effects of heparin and splenectomy on sur-vival and plasma fibronectin levels in rat peritonitis. J Surg Res 1986; 40:611-616 (Pubitemid 16033069)
34. Margaretten W, McKay DG, Phillips LL: The effect of heparin on endotoxin shock in the rat. Am J Pathol 1967; 51:61-68
35. O'Leary JP, Malik FS, Donahoe RR, et al: The effects of a minidose of heparin on peritonitis in rats. Surg Gynecol Obstet 1979; 148: 571-575 (Pubitemid 9147092)
36. Onda M, Toba M, Andoh T, et al: Ultrastruc-tural studies of experimental endotoxin shock in the liver and spleen: Therapeutic effects of low-dose heparin on reticuloendothelial distur-bances. Circ Shock 1986; 18:11-19 (Pubitemid 16174738)
37. Priano LL, Wilson RD, Traber DL: Lack of significant protection afforded by heparin during endotoxic shock. Am J Physiol 1971; 220:901-905
38. Prinz RA, Shuber Z, Fareed J, et al: Effect of heparin and heparin fractions on experimen-tal abscess formation. Arch Surg 1986; 121: 1173-1176 (Pubitemid 17177262)
39. Schiffer ER, Reber G, De Moerloose P, et al: Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med 2002; 30:2689-2699 (Pubitemid 36870571)
40. Slofstra SH, van't Veer C, Buurman WA, et al: Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med 2005; 33:1365-1370 (Pubitemid 40827391)
41. Smith EF 3rd, Kinter LB, Jugus M, et al: Effect of the thrombolytic agent, streptoki-nase, on the responses to endotoxemia in conscious rats. Circ Shock 1988; 25:85-94
42. Sun Y, Williams CH, Hardaway RM, et al: The effect of heparinization on intra-abdominal infection and acute pulmonary failure. Int Surg 1997; 82:367-370 (Pubitemid 27500939)
43. Vela AR, Littleton JC, O'Leary JP: The effects of minidose heparin and low molecular weight heparin on peritonitis in the rat. Am Surg 1999; 65:473-477 (Pubitemid 29200915)
44. Yang S, Hauptman JG: The efficacy of heparin and antithrombin III in fluid-resuscitated cecal ligation and puncture. Shock 1994; 2:433-437
45. Pittet J-F, Morel DR, Steinig DA, et al: Ben-eficial effect of heparin on a lethal constant rate infusion of E. coli endotoxin in sheep. Am Rev Respir Dis 1989; 139:A271
46. Schirmer WJ, Schirmer JM, Naff GB, et al: Heparin's effect on the natural history of sepsis in the rat. Circ Shock 1987; 21:363
47. Choi G, Vlaar AP, Schouten M, et al: Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not in-flammation. Eur Respir J 2007; 30:423-428 (Pubitemid 351182063)
48. Cornet AD, Smit EG, Beishuizen A, et al: The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98:579-586 (Pubitemid 47412883)
49. Papareddy P, Rydengard V, Pasupuleti M, et al: Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 2010; 6:e1000857
50. Sun H, Wang X, Degen JL, et al: Reduced thrombin generation increases host suscep-tibility to group A streptococcal infection. Blood 2009; 113:1358-1364
51. Hara S, Asada Y, Hatakeyama K, et al: Ex-pression of tissue factor and tissue factor pathway inhibitor in rats lungs with lipopo-lysaccharide-induced disseminated intravas-cular coagulation. Lab Invest 1997; 77: 581-589 (Pubitemid 28018778)
52. Leclerc J, Pu Q, Corseaux D, et al: A single endotoxin injection in the rabbit causes pro-longed blood vessel dysfunction and a proco-agulant state. Crit Care Med 2000; 28: 3672-3678
53. Hofstra JJ, Cornet AD, de Rooy BF, et al: Nebulized antithrombin limits bacterial out-growth and lung injury in Streptococcus pneumoniae pneumonia in rats. Crit Care 2009; 13:R145
54. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explana-tion and elaboration. Ann Intern Med 2009; 151:w65-w94